Trial Profile
An Open-label, Dose Escalation Phase 1 Study to Investigate HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2, in Patients With Advanced Solid Tumors Refractory to Standard Therapy
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Vulinacimab (Primary)
- Indications Carcinoma; Liver cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Henlix Biotech
- 28 Jul 2019 Status changed from recruiting to discontinued.
- 18 Apr 2018 New trial record